← back to search

Jiansong Ji

Wenzhou Medical University · CN
Area of research
Hepatology · Surgery
Research interest
Research focused on Hepatocellular carcinoma and Colorectal cancer, with related work in Immunotherapy, Gastroenterology, Immune system. Notable publications include 'Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)', 'Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases', and 'Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial'.
h-index
citations
1,243
works
17
NIH funding
primary concept
email

Recent publications

Sweetener aspartame aggravates atherosclerosis through insulin-triggered inflammation
Cell Metabolism 2025cited by 45position: middledoi
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)
Hepatology 2025cited by 6position: middledoi
SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.
Journal of Clinical Oncology 2025cited by 1position: middledoi
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
EClinicalMedicine 2024cited by 136position: middledoi
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
Signal Transduction and Targeted Therapy 2023cited by 274position: middledoi
Novel online calculator to predict reduced risk of early recurrence from adjuvant transarterial chemoembolisation for patients with hepatocellular carcinoma
eGastroenterology 2023cited by 12position: middledoi
A Novel Model for the Screening of Varices in Patients With Compensated Cirrhosis: An International Multicenter Study
SSRN Electronic Journal 2022cited by 0position: middledoi
Transcatheter Arterial Infusion Combined With Radioactive Particles in the Treatment of Advanced Body/Tail Pancreatic Cancer
Pancreas 2021cited by 2position: middledoi
T-cell-based immunotherapy in colorectal cancer
Cancer Letters 2020cited by 129position: middledoi
Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases
Cancer Letters 2019cited by 242position: middledoi
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
Therapeutic Advances in Medical Oncology 2019cited by 102position: lastdoi
Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres<sup>®</sup> in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres<sup>®</sup> Transarterial Chemoembolization in Liver Cancer (CTILC) Study
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2019cited by 27position: middledoi
The Comprehensive Analysis of Efficacy and Safety of CalliSpheres<sup>®</sup> Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2019cited by 24position: middledoi
Functional magnetic resonance imaging-based assessment of terlipressin vs. octreotide on renal function in cirrhotic patients with acute variceal bleeding (CHESS1903): study protocol of a multicenter randomized controlled trial
Annals of Translational Medicine 2019cited by 5position: middledoi
Retracted: Global microarray profiling identified <i>hsa_circ_0064428</i> as a potential immune-associated prognosis biomarker for hepatocellular carcinoma
Journal of Medical Genetics 2018cited by 74position: lastdoi
Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial
The Lancet Oncology 2014cited by 151position: middledoi
LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo
Tumor Biology 2014cited by 13position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Minjiang Chen · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2018–2019)Di Zhu · South China Agricultural University2 papers (2019–2020)Wenhui Wang · Beijing Institute of Technology2 papers (2014–2021)Mengxuan Yang · Sun Yat-sen University2 papers (2019–2020)Maoquan Li · Tongji University2 papers (2018–2021)Zhongwei Zhao · Kunming University of Science and Technology2 papers (2019–2020)Ming-Da Wang · Guangdong University of Technology1 papers (2023–2023)Jianjun Han · Shandong University1 papers (2021–2021)Yao Huang · Nanjing University of Chinese Medicine1 papers (2025–2025)Wei-Yue Chen · Army Medical University1 papers (2023–2023)Jin‐Yu Sun · Suzhou Municipal Hospital1 papers (2019–2019) · 1 papers (2025–2025)Gao‐Jun Teng · Society of Interventional Radiology1 papers (2014–2014)Jingjing Song · Hebei Medical University1 papers (2019–2019)Qiaoyou Weng · Indiana University School of Medicine1 papers (2018–2018)Wenjing Xiong · Fuyang Normal University1 papers (2025–2025)Jundong Zhou · University of Oklahoma Health Sciences Center1 papers (2014–2014)Guoliang Shao · Wannan Medical College1 papers (2018–2018)Ting-Hung Chen · National Taiwan University1 papers (2023–2023)Wei‐Fu Lv · Anhui Medical University1 papers (2014–2014)